VR Logo

Brainstorm Cell Therapeutics Inc. (BCLI) download report


Healthcare | Biotechnology & Pharma Research

Brainstorm Cell Therapeutics Inc. (BCLI) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

IPO Date: 28-Aug-2003

Chief Exec. Officer: Mr. Chaim Lebovits

Co-Founder & Independent Vice Chair of the Board: Dr. Irit Arbel DSc, Ph.D.

Listing: NASDAQ: BCLI

Country: United States

Headquarters: New York, NY

Website: https://www.brainstorm-cell.com

Key Facts

Market cap: $100.34 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-23.16 Mln

Cash: $18.40 Mln

Total Debt: $5.56 Mln

Insider's Holding: 22.57%

Liquidity: Low

52 Week range: $2.65 - 4.46

Shares outstanding: 36,486,200

10 Years Aggregate:

  • CFO: $-112.18 Mln
  • EBITDA: $-126.95 Mln
  • Net Profit: $-129.47 Mln

Stock Performance

Time Period Brainstorm Cell Therapeutics (BCLI) S&P BSE Sensex S&P Small-Cap 600
YTD-31.25-9.18-18.78
1 month-7.72-4.78-8.00
3 months-18.15-9.66-13.65
1 Year-27.630.81-17.19
3 Years-11.3710.336.10
5 Years-7.9011.345.87
10 Years-4.0411.749.84
As on 01-Jul-2022
Year Brainstorm Cell Therapeutics (BCLI) S&P Small-Cap 600 S&P BSE Sensex
2021-11.6025.2721.99
20205.729.5715.75
201920.5620.8614.38
2018-9.39-9.705.87
201754.3311.7327.91
2016-11.1924.741.95
2015-39.92-3.36-5.03